US Pharma MarketingALK’s EURneffy secures MHRA approval for anaphylaxis treatment
ALK’s EURneffy secures MHRA approval for anaphylaxis treatment is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
ALK has received marketing authorisation from the MHRA for EURneffy 1mg, a needle-free adrenaline treatment for children with anaphylaxis.
Source: Pharmaceutical Technology